| Name | Title | Contact Details |
|---|---|---|
Adam Veness |
Senior Vice President and General Counsel | Profile |
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.
Solarea Bio is a preclinical-stage biotechnology company in Cambridge, MA developing new microbiome-based solutions to some of the world`s largest health problems.
Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.